scholarly journals Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia

2007 ◽  
Vol 60 (5) ◽  
pp. 1131-1136 ◽  
Author(s):  
B. C. Opmeer ◽  
R. el Moussaoui ◽  
P. M. M. Bossuyt ◽  
P. Speelman ◽  
J. M. Prins ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Community Acquired Pneumonia ◽  
Hospitalized Patients ◽  
Severe Community Acquired Pneumonia

scholarly journals Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study

2018 ◽  
Vol 43 ◽  
pp. 183-189 ◽  
Author(s):  
J.M. Pereira ◽  
J. Gonçalves-Pereira ◽  
O. Ribeiro ◽  
J.P. Baptista ◽  
F. Froes ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Community Acquired Pneumonia ◽  
Severe Community Acquired Pneumonia

scholarly journals Efficacy of azoximer bromide in the treatment of hospitalized patients with moderate to severe community-acquired pneumonia

2021 ◽  
pp. 106-117
Author(s):  
S. K. Zyryanov ◽  
O. I. Butranova ◽  
A. V. Ershov ◽  
Z. Sh. Manasova
Keyword(s):  
Combination Therapy ◽  
Community Acquired Pneumonia ◽  
Hospitalized Patients ◽  
Study Group ◽  
Therapy Regimen ◽  
Duration Of Hospital Stay ◽  
Comparator Group ◽  
Group 2 ◽  
Severe Community Acquired Pneumonia ◽  
Group 1

Introduction. The high incidence of community-acquired pneumonia and the high complication rates in the cases of severe pneumonia actualize the search for new pharmacotherapy tools to improve the effectiveness of standard patient management regimens. A high level of severe inflammatory response underlies the high risk for developing septic complications of pneumonia, along with impaired immune responses.The aim is to evaluate the efficacy of azoximer bromide introduction in the combination therapy regimen for hospitalized patients with moderate to severe community-acquired pneumonia.Materials and methods. A prospective, open label, parallel group, randomized study comparing the efficacy of azoximer bromide introduction in the combination therapy of hospitalized patients with moderate to severe community-acquired pneumonia was conducted at the premises of Federal Scientific and Clinical Center for Reanimatology and Rehabilitation. 30 patients were included in the study group and 37 patients in the comparator group. The baseline characteristics were comparable in both groups. Results. The azoximer bromide introduction in the combination therapy of patients with community-acquired pneumonia led to a statistically significant reduction in the duration of hospital stay (Me (LQ; HQ): 9 (8; 10) days for the study group and 13 (10; 14) days for the comparator group, (p = 0.000078), duration of ICU stay (Me (LQ; HQ) 2 days (1.5; 2.5) and 5 days (5.0; 6.0), respectively, (p = 0.00001), the duration of febrile fever 5 (± 0.6) days versus 10 (± 1.2) days (p = 0.0000), the incidence of acute respiratory failure (13.33% in group 1 versus 37.84% in group 2, p = 0.024) and septic shock (10% in group 1 versus 32.43% in group 2, p = 0.0285).Conclusions. The azoximer bromide introduction in the standard therapy regimen for patients with community-acquired pneumonia allowed to reduce the duration of hospital stay, the duration of ICU stay, the length of febrile fever, the incidence of septic shock and respiratory failure. The possible mechanisms of action may include a reduction of the severe inflammatory reactions and an optimization of the patient's immune response to the infectious process.

scholarly journals Short duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia: results from the CAPO International Cohort Study

2017 ◽  
Vol 1 (3) ◽  
Author(s):  
Alejandro Chirino Navarta ◽  
Paula Peyrani ◽  
Timothy L. Wiemken ◽  
Marcos I. Restrepo ◽  
James D. Chalmers ◽  
...  
Keyword(s):  
Cohort Study ◽  
Antibiotic Therapy ◽  
Short Duration ◽  
Community Acquired Pneumonia ◽  
Hospitalized Patients

scholarly journals Antimicrobial switch therapy in pediatric patients hospitalized by uncomplicated community-acquired pneumonia

2020 ◽  
Vol 11 (3) ◽  
pp. 482
Author(s):  
Ronaldo MORALES-JUNIOR ◽  
Anna C. BARRIENTOS ◽  
Raquel M. SCALCO ◽  
Aline G. FEVEREIRO ◽  
Sulim ABRAMOVICI ◽  
...  
Keyword(s):  
Length Of Stay ◽  
Antibiotic Therapy ◽  
Length Of Hospital Stay ◽  
Venous Access ◽  
Cross Sectional Study ◽  
Community Acquired Pneumonia ◽  
Cross Sectional ◽  
Clinical Criteria ◽  
Switch Therapy ◽  
Severe Community Acquired Pneumonia

Objective: To evaluate the duration of intravenous (IV) antibiotic therapy and the practice of switch therapy to oral in the treatment of children aged 2 months to 5 years with uncomplicated severe community acquired pneumonia (CAP) in a pediatric public hospital. Methods: Retrospective, observational and cross-sectional study in which patients who started IV ampicillin treatment were selected. The patients were classified as “eligible” or “ineligible” to undergo switch therapy after 48 and 72 hours of hospitalization according to clinical criteria. Patients with length of stay <or ≥7 days were compared regarding demographic characteristics and antibiotic therapy, considering p <0.05 significant. Results: Eighty-six patients were evaluated, aged 14.4 (IQR: 10.8-22.7) months. The duration of IV therapy was 4 (IQR: 3-6) days; 56% of patients were classified as eligible for switch therapy within 48h and 74% as eligible within 72h. However, only 19 cases (22%) underwent switch therapy at the appropriate time. The main reason for the transition was the accidental loss of venous access (61%). The group with length of stay <7 days had a higher rate of switch and, consequently, shorter IV therapy duration (p <0.01). Conclusion: The switch therapy in the first 48 to 72 hours is not routinely used in the clinical practice in patients hospitalized with CAP. The findings warn of the need for institutional initiatives on this practice, aiming at improving the quality of care with shorter IV therapy duration and impact on length of hospital stay.

Sign in / Sign up

Export Citation Format

Share Document